Indee Labs
Indee Labs, based in Berkeley, CA, specializes in developing Hydropore™, a non-viral intracellular delivery system for T cell immunotherapy, utilizing microfluidic vortex shedding technology.
Services
Indee Labs provides innovative solutions for the discovery, development, and manufacturing of engineered cell therapies. Their offerings include a patented technology for the rapid delivery of small molecules, nucleic acids, proteins, and gene-editing complexes to immune cells. The company's scalable and efficient technology, Hydropore™, accelerates the process of engineered cell therapy development while maintaining cell viability and function.
Products
Indee Labs' primary product is Hydropore™, a scalable and efficient technology that utilizes microfluidic vortex shedding (µVS) for the rapid delivery of materials to immune cells. Designed for research use only (RUO) and developed with regulatory readiness in mind, Hydropore™ is suitable for high-throughput pooled screening of small volumes. All materials in the system's flow path are medical-grade or USP Class VI implantable-grade, ensuring high standards for research applications.
Founders
Indee Labs was founded by a team that participated in the Y-Combinator W17 batch. Comprised of experts in healthcare, drug discovery, and drug delivery, the team's mission is to revolutionize T cell immunotherapy through innovative, non-viral intracellular delivery systems.
Industry
Indee Labs operates within the healthcare industry, specifically focusing on drug discovery and delivery. Their advanced technology aims to enhance T cell immunotherapy through non-viral intracellular delivery methods. By addressing key challenges in the field, Indee Labs contributes to the improvement of cell engineering processes for therapeutic applications.
Technology
Hydropore™, the core technology developed by Indee Labs, leverages microfluidic vortex shedding (µVS) for non-viral intracellular delivery. This method allows for the rapid and efficient transfer of various materials, such as small molecules, nucleic acids, proteins, and gene-editing complexes, into immune cells. The technology is designed to preserve cell viability and function, making it an ideal solution for the research and development of engineered cell therapies.